Clinical Trials Browser

Neoplasms, Germ Cell and Embryonal, Ovarian Neoplasms, Sarcoma, Thyroid Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Lymphoma, Extranodal NK-T-Cell

NCT03563729 2023-07-13

MEMBRAINS

Phase 2 Recruiting

80 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT05255666 2023-07-11

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

Phase 2 Withdrawn

BreastCNS

Brain Neoplasms, Triple Negative Breast Neoplasms

NCT05366062 2022-05-13

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

Phase 2 Not yet recruiting

28 enrolled

CNS

Glioma

NCT02798406 2021-07-15

CAPTIVE

Phase 2 Completed

49 enrolled

CNSSarcoma

Brain Neoplasms, Disease, Glioblastoma, Glioma, Neoplasms, Neoplasms, Nerve Tissue, Nervous System Diseases, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Gliosarcoma

NCT02085070 2021-03-24

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

Phase 2 Completed

65 enrolled 10 charts

CNSDermatologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02337491 2020-12-22

Pembrolizumab +/- Bevacizumab for Recurrent GBM

Phase 2 Completed

80 enrolled 13 charts

CNS

Glioblastoma, Recurrence

Clinical Trials

Palbociclib and Pembrolizumab In Central Nervous System Metastases

Pembrolizumab, Olaparib, and Temozolomide for People With Glioma

Surgical Pembro +/- Olaparib w TMZ for rGBM

Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

2-THE-TOP

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

MATVAC-1

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

OPTIMUS PRIME

Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma

Pembro+Chemo in Brain Mets

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

TROPICAL-1

Ferumoxytol MRI in Assessing Response to Pembrolizumab in Patients With Glioblastoma

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Abemaciclib + Pembrolizumab In Glioblastoma

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Pembrolizumab And Lenvatinib In Leptomeningeal Metastases

LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma

Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

A Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma

Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma

Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

BEPCOME-MB

Pembrolizumab In Central Nervous System Metastases

AcSé

MEMBRAINS

Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab

CAPTIVE

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

Pembrolizumab +/- Bevacizumab for Recurrent GBM